Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling.

ABSTRACT: Prostate cancer (PC) is the most frequently diagnosed malignancy and a leading cause of cancer deaths in US men. Many PC cases metastasize and develop resistance to systemic hormonal therapy, a stage known as castration-resistant prostate cancer (CRPC). Therefore, there is an urgent need to develop effective therapeutic strategies for CRPC. Traditional drug discovery pipelines require significant time and capital input, which highlights a need for novel methods to evaluate the repositioning potential of existing drugs. Here, we present a computational framework to predict drug sensitivities of clinical CRPC tumors to various existing compounds and identify treatment options with high potential for clinical impact. We applied this method to a CRPC patient cohort and nominated drugs to comba

SUBMITTER: Zhang W 

PROVIDER: S-EPMC10151558 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature